InsidersTradesSigma
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (1 ops.)
Insider track record
OtherDisclosed buys
3
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the detailed record of transactions filed by Gall Matthew. Director active across 2 companies, notably iTeos Therapeutics, Inc.. Aggregated, 8 filings have been recorded. Breakdown: 3 buys · 1 sell. Total volume traded: €390k. Activity tracked since 16 June 2021. The latest transaction was disclosed on 7 March 2025 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Gall Matthew
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations8 total
89,429 sharesCommon StockSEC:0000950170-25-112236:0
24,000 shares0Common StockSEC:0000950170-25-037512:0
5,000 shares@ US$7.7274.3% of flowCommon StockSEC:0000950170-24-128956:0
Canonical exit: 17 Feb 2025 (T+90)
41,000 shares0Common StockSEC:0000950170-23-068901:0
5,000 shares@ US$8.374.6% of flowCommon StockSEC:0001209191-23-052709:0
Canonical exit: 10 Jan 2024 (T+90)
5,000 shares@ US$46.4543.9% of flowCommon StockSEC:0001209191-21-071435:0
14,429 shares@ US$6.1616.5% of flowCommon StockSEC:0001209191-21-060297:0
5,000 shares@ US$26.089323.3% of flowCommon StockSEC:0000899243-21-024236:0
Canonical exit: 14 Sept 2021 (T+90)
8 of 8 declarations
About Gall Matthew
Matthew Gall is a director at iTeos Therapeutics, Inc.
